文献速递脊柱关节炎

银屑病关节炎生物制剂转换治疗综述

Switching biologics in the treatment of psoriatic arthritis.
PubMed 文献 · Semin Arthritis Rheum · 2017-02-08

本文综述银屑病关节炎(PsA)生物制剂转换策略。文献数据显示既往TNFi治疗会降低阿达木单抗、依坦那西普和乌司奴单抗的应答,而英夫利西单抗疗效与既往bDMARD无关;乌司奴单抗和司库奇尤单抗在≥1种TNFi失败者中优于安慰剂。结论认为转换bDMARD是治疗失败后的推荐策略,不同机制药物可能更优。

要点

  • PsA治疗失败后转换bDMARD是推荐策略,需综合疾病特征、合并症和用药史选择药物。
  • 既往TNFi治疗可能降低阿达木单抗、依坦那西普和乌司奴单抗的应答。
  • 英夫利西单抗疗效独立于既往bDMARD治疗,不同机制bDMARD可能是更优选择。

核心结论

  • 对治疗失败的PsA患者,转换bDMARD治疗是推荐策略。
  • 转换TNFi对许多患者有效,但不同作用机制的bDMARD可能是更优替代选择。

研究设计与样本

  • 本文为综述,先评估PsA治疗推荐以识别bDMARD转换的共识指南,再以psoriatic arthritis、switch/switching、biologic和TNF/tumor necrosis factor为检索词在PubMed进行文献检索,纳入报告PsA患者不同bDMARD间转换数据的研究。

主要发现

  • PsA中bDMARD转换的临床文献数据有限。
  • 既往接受TNFi治疗后,阿达木单抗、依坦那西普和乌司奴单抗的应答较低。
  • 英夫利西单抗的疗效独立于既往bDMARD治疗。
  • 在≥1种TNFi治疗失败的患者中,乌司奴单抗和司库奇尤单抗的疗效应答优于安慰剂。

临床怎么用

  • 选择转换药物时需考虑PsA疾病特征、合并症、心血管代谢危险因素、治疗史和患者偏好。
  • 对TNFi治疗失败的患者,可考虑换用不同作用机制的bDMARD。

局限性

  • PsA中bDMARD转换的临床文献数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Psoriatic arthritis (PsA) is a heterogeneous inflammatory disorder that requires targeted treatment based on clinical manifestations, symptom severity, comorbidities, and other factors. Moderate or severe peripheral arthritis symptoms are typically treated with disease-modifying antirheumatic drugs (DMARDs) or biologic DMARDs (bDMARDs), and early and aggressive treatment is recommended in order to prevent permanent damage. Although rheumatologists are now able to choose between several bDMARDs for PsA that have different chemical structures, pharmacokinetic properties, dosing regimens, immunogenicity, safety profiles, and mechanisms of action, there is a lack of typical patient profiles or detailed treatment algorithms that can be followed when patients require alterations in their therapeutic regimens. METHODS: PsA treatment recommendations were evaluated to identify consensus guidelines on switching between bDMARD therapies. PubMed literature searches were then conducted using the terms psoriatic arthritis, switch/switching, biologic, and TNF/tumor necrosis factor. Articles were deemed relevant if they presented data on switching between different bDMARDs in patients with PsA. RESULTS: Data from the clinical literature on switching bDMARD therapies in PsA are limited. Evidence suggests that response to adalimumab, etanercept, and ustekinumab is lower after previous tumor necrosis factor inhibitor (TNFi) therapy and the efficacy of infliximab is independent of previous bDMARD treatment. Trials of ustekinumab and secukinumab showed efficacy responses were greater compared with placebo in patients who failed to respond to ≥1 TNFi. CONCLUSION: Switching bDMARD therapies is a recommended strategy for patients who experience treatment failure. Many factors must be considered for determining which agent to switch to including PsA disease characteristics, comorbidities, cardiometabolic risk factors, treatment history, and patient preference. Switching between TNFis can be effective for many patients, but bDMARDs with different mechanisms of action may be superior alternatives.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Merola JF, Lockshin B, Mody EA, et al. Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum. 2017. PMID: 28363434. doi:10.1016/j.semarthrit.2017.02.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。